Details

Autor(en) / Beteiligte

• Patricia K. Sharkey
• John R. Graybill
• Johnson, Edward S.
• Stephen G. Hausrath
• Richard B. Pollard
• Antonia Kolokathis
• Mildvan, Donna
• Patty Fan-Havard
• Robert H. K. Eng
• Patterson, Thomas F.
• John C. Pottage, Jr
• Michael S. Simberkoff
• Wolf, Judith
• Meyer, Richard D.
• Renu Gupta
• Lily W. Lee
• David S. Gordon

Titel

Amphotericin B Lipid Complex Compared with Amphotericin B in the Treatment of Cryptococcal Meningitis in Patients with AIDS

Ist Teil von

• Clinical infectious diseases, 1996-02, Vol.22 (2), p.315-321

Ort / Verlag

Chicago, IL: University of Chicago Press

Erscheinungsjahr

1996

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• The study objective was to obtain preliminary information regarding the safety and efficacy of amphotericin B (AmB) lipid complex (ABLC) in the treatment of AIDS-associated cryptococcal meningitis. Of 55 patients randomly assigned to 6 weeks of therapy with ABLC (1.2-5.0 mg/[kg·d], with ascending doses for three sequential cohorts) or AmB (0.7-1.2 mg/[kg·d]), 46 received ≥ 12 doses. Transfusion requirements, mean decreases in hemoglobin level, and mean increases in creatinine level were significantly greater with AmB than with ABLC. The total number of adverse events, infusion-related events, and occurrences of hypomagnesemia and hypokalemia associated with each form of therapy were similar. Among 21 recipients of ABLC at a dosage of 5 mg/kg (daily for 2 weeks and then thrice weekly for 4 weeks), symptoms and signs resolved for 18 (86%). Of those receiving ≥ 12 doses of ABLC, cultures converted to negative for 8 (42%), were undeterminable for 3 (16%), and remained positive for 8 (42%) despite resolution of symptoms. Although preliminary, these data suggest ABLC has significant activity in patients with AIDS-associated cryptococcal meningitis. Because this formulation has less hematologic and renal toxicity than does AmB, further evaluation of ABLC is warranted.